Sorafenib Dose Escalation in Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

April 30, 2009

Study Completion Date

January 31, 2011

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.

Trial Locations (22)

13385

Marseille

20133

Milan

27100

Pavia

30625

Hanover

33000

Bordeaux

33081

Aviano

35043

Marburg

37044

Tours

44805

Nantes

55131

Mainz

72076

Tübingen

75475

Paris

85925

La Roche-sur-Yon

07740

Jena

10-226

Olsztyn

02-781

Warsaw

04-141

Warsaw

50 - 556

Wroclaw

SW3 6JJ

London

M20 4BX

Greater Manchester

CF14 7TB

Cardiff

G12 0YN

Glasgow

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00618982 - Sorafenib Dose Escalation in Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter